Lutropin alfa

Drug Profile

Lutropin alfa

Alternative Names: LHadi; Lutropin; Lutropin-α; Luveris; r-hLH; Recombinant luteinising hormone

Latest Information Update: 14 Jul 2014

Price : $50

At a glance

  • Originator Merck Serono
  • Class Infertility therapies; Menotropins; Peptide hormones; Pituitary gonadotropins
  • Mechanism of Action Luteinising hormone stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Female infertility
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 20 Oct 2004 Clinical data have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top